List of Excipients in Branded Drug QUZYTTIR

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
ESTEVE PHARMACEUTICALS SA	QUZYTTIR	cetirizine hydrochloride	68118-100	HYDROCHLORIC ACID
ESTEVE PHARMACEUTICALS SA	QUZYTTIR	cetirizine hydrochloride	68118-100	SODIUM CHLORIDE
ESTEVE PHARMACEUTICALS SA	QUZYTTIR	cetirizine hydrochloride	68118-100	SODIUM HYDROXIDE
ESTEVE PHARMACEUTICALS SA	QUZYTTIR	cetirizine hydrochloride	68118-100	WATER
TerSera Therapeutics LLC	QUZYTTIR	cetirizine hydrochloride	70720-100	HYDROCHLORIC ACID

Quzyttir Excipient Strategy and Commercial Opportunities

Last updated: September 4, 2026

Quzyttir is a preservative-free, 10 mg/mL cetirizine hydrochloride injection for acute urticaria in adults and pediatric patients six months and older. Its formulation uses a narrow excipient set, with sodium chloride and water for injection, while hydrochloric acid and/or sodium hydroxide may be used for pH adjustment.[1] The commercial opportunity is less likely to come from new excipients than from improved presentation, dose flexibility, administration efficiency, and hospital procurement economics.

What is Quzyttir and how is it administered?

Quzyttir is the injectable formulation of cetirizine hydrochloride, a second-generation H1 antihistamine. The FDA approved Quzyttir under NDA 210590 in 2019 for the treatment of acute urticaria in adults and children six months of age and older.[1,2]

Attribute	Quzyttir
Active ingredient	Cetirizine hydrochloride
Strength	10 mg/mL
Dosage form	Injectable solution
Routes	Intravenous and intramuscular
Presentation	Single-dose vial
Indication	Acute urticaria
Pediatric use	Patients six months and older
Preservative	None identified in the FDA labeling
NDA	210590
Sponsor marketed in the U.S.	TerSera Therapeutics
FDA approval	2019

The product is administered intravenously over one to two minutes or by intramuscular injection. The label provides age-based dosing, including lower doses for young children.[1]

Quzyttir is positioned for emergency departments, hospitals, urgent-care facilities, outpatient infusion centers, and settings where oral administration is impractical or delayed.

What excipients are used in Quzyttir?

Quzyttir uses a minimal aqueous parenteral formulation. The FDA prescribing information identifies sodium chloride and water for injection as inactive ingredients. Hydrochloric acid and sodium hydroxide may be used to adjust pH.[1]

Excipient or processing component	Function	Commercial relevance
Water for injection	Injectable vehicle	Standard parenteral solvent with broad regulatory familiarity
Sodium chloride	Tonicity adjustment	Supports physiological osmolality and injection tolerability
Hydrochloric acid	pH adjustment	Enables final pH control
Sodium hydroxide	pH adjustment	Enables final pH control
Preservative	Not identified	Supports single-dose, preservative-free positioning

The formulation strategy reduces excipient-related regulatory and supply-chain complexity. It avoids preservatives, surfactants, complex co-solvent systems, and novel solubilizers. That design can simplify manufacturing scale-up and reduce the number of variables affecting extractables, leachables, and injection-site tolerability.

The limited excipient burden also reduces the number of obvious formulation patents available to a competitor. A competitor cannot easily obtain meaningful exclusivity merely by using the same basic saline vehicle. Commercial differentiation would require a distinct formulation, device, dosage presentation, stability profile, or manufacturing process.

How strong is the Quzyttir formulation strategy?

The formulation is commercially practical but not inherently difficult to replicate. Cetirizine hydrochloride is water soluble, and the marketed product does not depend on a complex delivery system.

Formulation strengths

The main strengths are:

• Preservative-free single-dose administration.
• Straightforward aqueous composition.
• IV and IM compatibility.
• Low excipient burden.
• Familiar hospital handling.
• Reduced risk of excipient-mediated hypersensitivity relative to more complex injectable systems.
• Potentially efficient fill-finish operations.

These attributes matter in acute-care purchasing. Hospitals generally prefer products that can move through standard medication-use protocols without special preparation, refrigeration requirements, dilution steps, or unusual administration equipment.

Formulation limitations

The same simplicity limits differentiation. A basic cetirizine injection formulation may be vulnerable to:

• Abbreviated new drug application competition.
• 505(b)(2) products using alternative presentations.
• Hospital-compounded or repackaged alternatives, subject to applicable federal and state requirements.
• Price competition from oral cetirizine and other injectable antihistamines.
• Product substitution based on contract purchasing rather than clinical differentiation.

The principal commercial barrier may be market adoption, not formulation science. Clinicians must see a benefit from parenteral cetirizine over oral cetirizine, injectable diphenhydramine, or other acute-care protocols.

What formulation patents could protect Quzyttir or competing products?

Potential patentable subject matter includes the composition, pH range, concentration, stability profile, container closure, dosing presentation, and manufacturing process. The strongest claims would normally require a technically defined feature that produces an unexpected result, such as improved stability, reduced degradation, improved tolerability, or a longer room-temperature shelf life.

Composition claims

A composition patent could attempt to cover:

• Cetirizine hydrochloride at a defined concentration.
• Sodium chloride within a specified tonicity range.
• A defined pH window.
• Limits on impurities or degradation products.
• Absence of preservatives or selected excipients.
• Specific concentration ratios between active ingredient and tonicity agent.

Broad claims covering cetirizine hydrochloride in water with sodium chloride would face potential validity and obviousness challenges if similar injectable antihistamine formulations or cetirizine solution disclosures were publicly available before filing.

Stability claims

Stability claims may be more defensible if the applicant demonstrates:

• Reduced cetirizine degradation under accelerated conditions.
• Improved stability in a defined vial or syringe material.
• Protection from light or oxygen.
• Reduced particulate formation.
• Extended in-use stability after vial access.
• Compatibility with IV administration materials.

A stability patent is commercially relevant only if the claimed parameters distinguish the marketed product or create a meaningful operational advantage.

Device and presentation claims

A prefilled syringe, unit-dose cartridge, or ready-to-administer delivery system could support separate intellectual property. Claims could focus on:

• A fixed cetirizine dose for emergency use.
• A pediatric dose presentation.
• A syringe designed for slow IV administration.
• A tamper-evident single-use system.
• A unit-dose package that reduces medication errors.
• A combination of syringe, dose markings, and administration instructions.

Device protection may be more commercially durable than a narrow excipient patent because it can address workflow and medication safety.

What commercial opportunities exist for Quzyttir excipients and presentation?

The largest opportunities involve converting the current vial into more convenient hospital-use formats.

1. Pediatric dose presentations

Quzyttir is approved for patients six months and older, but a 10 mg/mL vial creates dose-measurement and wastage issues for young children. A commercial developer could pursue:

• 2.5 mg unit-dose presentations.
• 5 mg unit-dose presentations.
• Low-volume prefilled syringes.
• Clearly marked pediatric syringes.
• Packaging that reduces vial entry and dose conversion errors.

For example, a 2.5 mg dose would require 0.25 mL at the marketed concentration. A 5 mg dose would require 0.5 mL. A dedicated unit-dose format could reduce calculation and withdrawal steps, although it would introduce additional container-closure, extractables, fill-volume, and regulatory requirements.

2. Ready-to-administer prefilled syringes

A prefilled syringe could eliminate vial access, needle transfer, and dose withdrawal. The commercial value would be highest in emergency departments and ambulances, where time and medication preparation are important.

Key technical requirements would include:

• Syringe-material compatibility.
• Low extractables and leachables.
• Plunger and stopper compatibility.
• Protection from light and oxygen if needed.
• Reliable dose accuracy at low fill volumes.
• Stability through shipping and storage.
• Compatibility with common IV extension sets.

The main risk is cost. A prefilled syringe can materially increase packaging and fill-finish expenses compared with a simple vial. The business case requires a price premium or measurable labor and waste savings.

3. Extended room-temperature stability

Hospitals value products that can be stored in automated dispensing cabinets and emergency medication trays. A formulation or packaging program that extends room-temperature storage could support:

• Wider emergency-department deployment.
• Lower cold-chain dependence.
• Reduced pharmacy preparation.
• Fewer stockouts caused by storage restrictions.
• Easier use in urgent-care and outpatient settings.

This opportunity depends on demonstrated stability rather than the mere selection of a new excipient. A buffer, antioxidant, chelator, or oxygen-reducing package could be considered, but each additional component adds regulatory and compatibility burdens.

4. Low-waste packaging

A single-dose vial may produce residual volume after administration, particularly when pediatric doses are drawn. Smaller fill volumes and multiple unit-dose configurations could reduce discard.

Potential commercial formats include:

Format	Primary benefit	Main challenge
1 mL vial	Current standard presentation	Pediatric withdrawal and residual waste
0.25 mL prefilled syringe	Exact 2.5 mg dose	Low-volume fill accuracy and higher packaging cost
0.5 mL prefilled syringe	Exact 5 mg dose	Limited use for adult 10 mg dosing
1 mL prefilled syringe	Adult dose convenience	Higher unit cost
Multi-dose vial	Lower packaging cost per dose	Preservative and in-use stability requirements
Dual pediatric pack	Broader pediatric coverage	More stock-keeping units

A multi-dose vial is less attractive because it could require a preservative, an in-use stability program, and a different risk-benefit profile. The current single-dose, preservative-free strategy is better aligned with acute-care infection-control practices.

How does Quzyttir compare with oral cetirizine and injectable antihistamines?

Quzyttir competes on route of administration and operational convenience rather than on a new pharmacologic mechanism.

Product category	Advantage	Limitation relative to Quzyttir
Oral cetirizine	Low cost, established use, convenient	Not suitable when oral administration is impractical
Injectable cetirizine	Rapid parenteral administration and acute-care use	Higher cost and injection-related workflow
Injectable diphenhydramine	Established emergency-department familiarity	Greater sedation and anticholinergic burden in many patients
Other injectable antihistamines	May fit local protocols	Variable availability, safety profile, and clinical preference
Epinephrine	Critical for anaphylaxis	Not a substitute for antihistamine treatment of uncomplicated urticaria

Quzyttir should not be positioned as a replacement for epinephrine in anaphylaxis. The product is indicated for acute urticaria, while epinephrine remains the emergency treatment for life-threatening allergic reactions involving airway compromise, hypotension, or other anaphylaxis features.[1]

The strongest commercial message is operational: injectable cetirizine may offer a non-sedating or less-sedating alternative to first-generation injectable antihistamines in selected patients, while avoiding oral administration.

What is the FDA regulatory status of Quzyttir?

Quzyttir was approved through an NDA rather than an ANDA because the product introduced an injectable cetirizine formulation for an indication and route not covered by the existing oral cetirizine products.[1,2]

The regulatory pathway creates several implications:

• A competing injectable product may require an NDA or 505(b)(2) application, depending on the proposed reliance strategy.
• A generic oral cetirizine product cannot automatically substitute for injectable cetirizine.
• A competitor would need to address parenteral safety, sterility, container closure, stability, and route-specific labeling.
• A formulation change may require a supplemental NDA, a new NDA, or another FDA pathway depending on the scope of the change.

The product’s approval does not mean that every future cetirizine injection can use an ANDA pathway. The correct route depends on reference-product eligibility, FDA-listed patents and exclusivities, formulation similarity, labeling, and the proposed reliance on existing findings.

What is the Orange Book and patent status of Quzyttir?

Quzyttir is associated with NDA 210590. FDA Orange Book analysis should distinguish among:

1. Listed patents for the reference drug.
2. Unexpired regulatory exclusivity.
3. Patent claims that may cover composition, use, or manufacture.
4. Patent litigation involving an ANDA applicant.
5. Commercial exclusivity that exists in practice even when no statutory exclusivity remains.

The three-year exclusivity associated with approval based on new clinical investigations would not ordinarily extend beyond the early post-approval period for a 2019 approval.[2] Any current competitive barrier therefore depends primarily on patent status, FDA listing decisions, product quality requirements, manufacturing capacity, and market economics.

Paragraph IV risk

A future ANDA or 505(b)(2) applicant could challenge listed patents through a Paragraph IV certification. Risk would depend on:

• Whether the relevant patent remains listed and unexpired.
• Whether the claims cover the injectable formulation or only a method of use.
• Whether the proposed product uses the same concentration, pH, excipient profile, and presentation.
• Whether the applicant can design around the claims.
• Whether the patent owner files suit within the statutory period.

The most commercially relevant claims would be those covering the injectable composition, stability conditions, or administration method. Broad method-of-use claims may have lower practical value if a competitor can seek a carve-out or market a product with compliant labeling that omits the protected use, subject to FDA requirements and litigation risk.

Publicly available regulatory materials should be reviewed against the current Orange Book before making a launch or litigation decision. Patent expiration cannot be inferred solely from the 2019 approval date.

Which companies could challenge or compete with Quzyttir?

The competitive field includes:

• Generic injectable manufacturers with sterile fill-finish capacity.
• 505(b)(2) developers specializing in reformulated hospital products.
• Specialty pharmaceutical companies with emergency-care portfolios.
• Contract manufacturers able to produce low-volume sterile vials or syringes.
• Companies developing ready-to-administer emergency medicines.

Potential entrants are more likely to compete through a differentiated presentation than through a novel cetirizine molecule. A prefilled syringe, pediatric dose, alternative container, or improved storage profile could support a distinct commercial proposition.

The largest manufacturing barriers are sterile processing, aseptic filling, particulate control, container-closure integrity, validated sterilization or sterile filtration, and reliable low-volume fill accuracy. These barriers reduce the number of credible competitors but do not create the same protection as a complex biologic manufacturing process.

What licensing opportunities exist around Quzyttir?

Licensing opportunities could arise in four areas:

Product rights

A regional partner could obtain rights for hospital and urgent-care distribution, especially in markets where injectable antihistamines are used routinely.

Device and packaging rights

A medical-device company could license a prefilled syringe, cartridge, or autoinjector presentation. An autoinjector would need a clear clinical and workflow rationale because cetirizine injection is not the emergency substitute for epinephrine.

Manufacturing rights

A sterile injectables manufacturer could provide capacity under a supply or license agreement. The value would depend on validated scale, vial and syringe capabilities, and the ability to support regulatory submissions.

Formulation rights

A formulation partner could develop a low-waste pediatric product, extended-stability product, or ready-to-administer presentation. The strongest deal structure would tie milestones to formulation selection, stability data, FDA filing, approval, and commercial supply.

No publicly confirmed major licensing transaction should be assumed without reviewing company disclosures, SEC filings, FDA records, or the applicable patent assignments.

What revenue exposure and launch scenarios apply to Quzyttir?

Publicly reported product-specific revenue for Quzyttir is limited. Market sizing should therefore use a bottom-up hospital model rather than extrapolating from total cetirizine sales.

Revenue depends on:

• Number of treated acute-urticaria cases.
• Hospital formulary adoption.
• Use in pediatric emergency care.
• Contract pricing.
• Vial wastage.
• Reimbursement and charge capture.
• Availability of oral alternatives.
• Competitor entry.
• Pharmacy labor savings from ready-to-use formats.

Scenario	Commercial effect
Current vial remains differentiated	Stable specialty injectable niche
Generic vial enters	Price erosion and formulary pressure
Pediatric unit dose launches	Higher unit economics and broader pediatric adoption
Prefilled syringe gains hospital contracts	Premium pricing with packaging-cost risk
Multiple entrants launch	Contract-driven pricing and lower margins
Product gains protocol inclusion	Higher utilization in emergency and urgent-care settings

The most attractive opportunity is a portfolio strategy that keeps the low-cost vial while adding one or two high-value unit-dose presentations. A full reformulation with multiple novel excipients would likely create more regulatory and manufacturing risk than commercial value.

Key Takeaways

• Quzyttir is a 10 mg/mL preservative-free cetirizine hydrochloride injection approved for acute urticaria in patients six months and older.
• Its excipient system is simple: sodium chloride and water for injection, with acid or base used for pH adjustment.
• The formulation is operationally attractive but not difficult to replicate on excipient selection alone.
• The strongest commercial opportunities are pediatric unit doses, prefilled syringes, low-waste packaging, and extended room-temperature stability.
• A multi-dose preserved vial is less aligned with the current product strategy because it would introduce in-use stability and preservative requirements.
• Future competitors are more likely to use 505(b)(2) or other NDA-based strategies than a straightforward oral-cetirizine generic pathway.
• Patent value depends on the current Orange Book record and the scope of any composition, stability, use, or manufacturing claims.
• The principal commercial risks are generic or reformulated entry, hospital price pressure, low utilization relative to oral cetirizine, and limited product-specific revenue visibility.
• The highest-value development path is incremental presentation innovation rather than a complex new excipient system.

FAQs

Can Quzyttir be reformulated without changing its FDA approval?

Minor manufacturing or excipient changes may be possible through an approved-product supplement, but the required FDA pathway depends on the nature and scale of the change. A new presentation or materially different formulation may require a new regulatory submission.

Is a preservative-free cetirizine injection commercially superior?

It can be superior in single-dose hospital use because it avoids preservative exposure and supports standard aseptic handling. The benefit is weaker for multi-dose packaging, where the absence of a preservative can create in-use stability and contamination-control issues.

Could a competitor patent a pediatric Quzyttir syringe?

Yes, a competitor could pursue claims covering a specific dose, fill volume, syringe configuration, packaging system, or method of administration. Patent strength would depend on novelty, nonobviousness, written description, enablement, and the ability to distinguish the product from known cetirizine injections.

Would an extended-stability Quzyttir product support premium pricing?

Potentially. Hospitals may pay more for a product that reduces refrigeration, pharmacy preparation, waste, or emergency medication stocking costs. Premium pricing would require documented stability and a measurable workflow benefit.

Is Quzyttir a substitute for injectable epinephrine?

No. Quzyttir is indicated for acute urticaria. Epinephrine remains the emergency treatment for anaphylaxis and other life-threatening systemic allergic reactions.[1]

References

1. U.S. Food and Drug Administration. (2023). Quzyttir (cetirizine hydrochloride injection) prescribing information. FDA.

2. U.S. Food and Drug Administration. (2019). FDA approves Quzyttir for acute urticaria. FDA.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

4. U.S. Food and Drug Administration. (2024). ANDA, 505(b)(2), and NDA regulatory pathways. FDA.

5. U.S. Food and Drug Administration. (2024). Guidance for industry: Container closure systems for packaging human drugs and biologics. FDA.